Pfizer (PFE) Receivables - Other (2009 - 2023)

Pfizer has disclosed Receivables - Other across 8 years of filings, most recently posting $57.0 million for Q2 2023.

• In Q2 2023, Receivables - Other fell 57.14% year-over-year to $57.0 million; the TTM figure through Apr 2023 stood at $57.0 million (down 57.14% YoY), while the FY2021 annual figure was $53.0 million, down 86.78% from the prior year.
• Receivables - Other eased to $57.0 million in Q2 2023, from $167.0 million in the prior quarter.
• Over the last five years, Receivables - Other for PFE reached as high as $871.0 million in Q2 2021 and fell as low as $53.0 million in Q4 2021.
• The 4-year median for Receivables - Other is $197.0 million (2021), against an average of $287.2 million.
• Annual changes were most pronounced in 2021 — Receivables - Other tumbled 86.78% — and 2022, when it slipped 15.23%.
• A 4-year view of Receivables - Other shows it stood at $401.0 million in 2020, then plunged by 86.78% to $53.0 million in 2021, then soared by 215.09% to $167.0 million in 2022, then sank by 65.87% to $57.0 million in 2023.
• According to Business Quant data, Receivables - Other over the past three periods registered $57.0 million, $167.0 million, and $272.0 million for Q2 2023, Q4 2022, and Q3 2022 respectively.